Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Amneal Pharmaceuticals ( (AMRX) ).
Amneal Pharmaceuticals reported its financial results for the third quarter of 2025, with net revenue reaching $785 million, a 12% increase from the previous year, and a net income of $2 million. The company’s growth was driven by key branded products like CREXONT® and new launches such as BREKIYA® in the migraine space, alongside a strong performance in their Affordable Medicines segment. Amneal updated its 2025 full-year guidance, reflecting increased expectations for adjusted EBITDA and diluted EPS, highlighting the company’s strategic positioning and momentum as it enters 2026.
The most recent analyst rating on (AMRX) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Amneal Pharmaceuticals stock, see the AMRX Stock Forecast page.
Spark’s Take on AMRX Stock
According to Spark, TipRanks’ AI Analyst, AMRX is a Neutral.
Amneal Pharmaceuticals’ strong revenue growth and robust cash flow management are significant strengths. The positive technical indicators and optimistic earnings call further bolster the stock’s outlook. However, the extremely high P/E ratio and challenges in profitability weigh down the overall score.
To see Spark’s full report on AMRX stock, click here.
More about Amneal Pharmaceuticals
Amneal Pharmaceuticals, Inc., headquartered in Bridgewater, NJ, is a global biopharmaceutical company that develops, manufactures, and distributes a diverse portfolio of over 290 pharmaceutical products, primarily within the United States. The company operates in the Affordable Medicines segment, focusing on complex product categories such as injectables and biosimilars, and the Specialty segment, which includes branded pharmaceuticals for central nervous system and endocrine disorders. Additionally, through its AvKARE segment, Amneal distributes pharmaceuticals for the U.S. federal government, retail, and institutional markets.
Average Trading Volume: 1,633,571
Technical Sentiment Signal: Buy
Current Market Cap: $3.28B
Learn more about AMRX stock on TipRanks’ Stock Analysis page.